Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jun 25:5:361-9.
doi: 10.2147/IJWH.S42770. Print 2013.

Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial

Josep Lluis Carbonell Esteve  1 , Rita Acosta, Yasmirian Pérez, Barbara Rodriguez, Isabel Seigler, Carlos Sanchez, Giuseppe Tomasi
Affiliations

Mifepristone versus placebo to treat uterine myoma: a double-blind, randomized clinical trial

Josep Lluis Carbonell Esteve et al. Int J Womens Health. .

Abstract

Objective: To evaluate the efficacy, safety, and quality of life of 5 mg mifepristone per day compared with a placebo in treating uterine fibroids.

Design: Randomized, double-blind clinical study.

Location: Eusebio Hernández Gynecology and Obstetrics Teaching Hospital, Havana, Cuba.

Subjects: One hundred twenty-four subjects with symptomatic uterine fibroids.

Treatment: One daily capsule of 5 mg mifepristone or a mifepristone placebo over 3 months.

Variables in evaluating safety: Changes in fibroid and uterine volumes, changes in symptom prevalence and intensity, and changes in quality of life.

Results: Three months into treatment, fibroid volume was reduced by 28.5% in the mifepristone group with an increase of 1.8% in the placebo group (P = 0.031). There were significant differences between the groups with respect to pelvic pain prevalence (P = 0.006), pelvic pressure (P = 0.027), rectal pain (P = 0.013), hypermenorrhea (P < 0.001), and metrorrhagia (P = 0.002) at the end of treatment. Amenorrhea was 93.1% and 4.3% in the mifepristone and placebo groups, respectively (P < 0.001). Treatment side effects were significantly greater in the mifepristone group. Estradiol levels did not differ significantly between the placebo and mifepristone groups at the end of treatment. Improvement in quality of life was significantly greater in the categories of "symptoms" (P = 0.004) and "activity" (P = 0.045) in the mifepristone group.

Conclusion: The 5 mg dosage of mifepristone presented significantly superior efficacy compared to the placebo.

Keywords: antiprogestins; fibroid; leiomyoma; mifepristone.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart for the trial.
Figure 2
Figure 2
Changes in the determinations of estradiol before and after treatment.
See this image and copyright information in PMC

References

    1. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243–250. - PubMed
    1. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Min Invasiv Gynecol. 2005;12(3):227–233. - PubMed
    1. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol. 2009;146(2):215–218. - PubMed
    1. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. A randomized controlled trial. Obstet Gynecol. 2006;108(6):1381–1387. - PubMed
    1. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas. Obstet Gynecol. 2008;112(5):1029–1036. - PubMed

LinkOut - more resources